

Eng King Tan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2360219/publications.pdf>

Version: 2024-02-01

271
papers

8,687
citations

57758

44
h-index

69250

77
g-index

284
all docs

284
docs citations

284
times ranked

11686
citing authors

#	ARTICLE	IF	CITATIONS
1	Midbrain-like Organoids from Human Pluripotent Stem Cells Contain Functional Dopaminergic and Neuromelanin-Producing Neurons. <i>Cell Stem Cell</i> , 2016, 19, 248-257.	11.1	628
2	Parkinson's disease: etiopathogenesis and treatment. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 795-808.	1.9	459
3	Parkinson disease and the immune system " associations, mechanisms and therapeutics. <i>Nature Reviews Neurology</i> , 2020, 16, 303-318.	10.1	254
4	Restless legs syndrome in an Asian population: A study in Singapore. <i>Movement Disorders</i> , 2001, 16, 577-579.	3.9	238
5	Pathogenic mutations in Parkinson disease. <i>Human Mutation</i> , 2007, 28, 641-653.	2.5	212
6	A sensitive two-photon probe to selectively detect monoamine oxidase B activity in Parkinson's disease models. <i>Nature Communications</i> , 2014, 5, 3276.	12.8	175
7	Historical Perspective: Models of Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2464.	4.1	174
8	Identification of Risk Loci for Parkinson Disease in Asians and Comparison of Risk Between Asians and Europeans. <i>JAMA Neurology</i> , 2020, 77, 746.	9.0	170
9	Resveratrol alleviates MPTP-induced motor impairments and pathological changes by autophagic degradation of α -synuclein via SIRT1-deacetylated LC3. <i>Molecular Nutrition and Food Research</i> , 2016, 60, 2161-2175.	3.3	136
10	Role of MicroRNAs in Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5649.	4.1	134
11	Large-Scale Whole-Genome Sequencing of Three Diverse Asian Populations in Singapore. <i>Cell</i> , 2019, 179, 736-749.e15.	28.9	126
12	Evidence of Inflammatory System Involvement in Parkinson's Disease. <i>BioMed Research International</i> , 2014, 2014, 1-9.	1.9	124
13	The role of gut dysbiosis in Parkinson's disease: mechanistic insights and therapeutic options. <i>Brain</i> , 2021, 144, 2571-2593.	7.6	119
14	Potassium channel dysfunction in human neuronal models of Angelman syndrome. <i>Science</i> , 2019, 366, 1486-1492.	12.6	118
15	Parkinson's disease in the Western Pacific Region. <i>Lancet Neurology</i> , The, 2019, 18, 865-879.	10.2	116
16	MDS evidence-based review of treatments for essential tremor. <i>Movement Disorders</i> , 2019, 34, 950-958.	3.9	108
17	Multiple <i>LRRK2</i> variants modulate risk of Parkinson disease: a Chinese multicenter study. <i>Human Mutation</i> , 2010, 31, n/a-n/a.	2.5	106
18	Whole-genome and whole-exome sequencing in neurological diseases. <i>Nature Reviews Neurology</i> , 2012, 8, 508-517.	10.1	99

#	ARTICLE	IF	CITATIONS
19	Genome-wide association study of Parkinson's disease in East Asians. <i>Human Molecular Genetics</i> , 2017, 26, ddw379.	2.9	94
20	The role of IgA in COVID-19. <i>Brain, Behavior, and Immunity</i> , 2020, 87, 182-183.	4.1	92
21	Superoxide drives progression of Parkin/PINK1-dependent mitophagy following translocation of Parkin to mitochondria. <i>Cell Death and Disease</i> , 2017, 8, e3097-e3097.	6.3	90
22	microRNAs and Neurodegenerative Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2015, 888, 85-105.	1.6	84
23	Chronic cerebral hypoperfusion enhances Tau hyperphosphorylation and reduces autophagy in Alzheimer's disease mice. <i>Scientific Reports</i> , 2016, 6, 23964.	3.3	82
24	Essential tremor-plus: a controversial new concept. <i>Lancet Neurology</i> , The, 2020, 19, 266-270.	10.2	82
25	Evidence of increased odds of essential tremor in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 993-997.	3.9	81
26	Flow Cytometry-Based Assessment of Mitophagy Using MitoTracker. <i>Frontiers in Cellular Neuroscience</i> , 2016, 10, 76.	3.7	80
27	Amyloid- β and Parkinson's disease. <i>Journal of Neurology</i> , 2019, 266, 2605-2619.	3.6	79
28	Botulinum toxin improves quality of life in hemifacial spasm: validation of a questionnaire (HFS-30). <i>Journal of the Neurological Sciences</i> , 2004, 219, 151-155.	0.6	75
29	Tryptophan-metabolizing gut microbes regulate adult neurogenesis via the aryl hydrocarbon receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	75
30	The Therapeutic Implications of Tea Polyphenols Against Dopamine (DA) Neuron Degeneration in Parkinson's Disease (PD). <i>Cells</i> , 2019, 8, 911.	4.1	69
31	Genetic Testing in Parkinson Disease. <i>Archives of Neurology</i> , 2006, 63, 1232.	4.5	67
32	MiRNA-128 regulates the proliferation and neurogenesis of neural precursors by targeting PCM1 in the developing cortex. <i>ELife</i> , 2016, 5, .	6.0	67
33	Effect of MDR1 Haplotype on Risk of Parkinson Disease. <i>Archives of Neurology</i> , 2005, 62, 460.	4.5	66
34	Association of <i>NOTCH2NLC</i> Repeat Expansions With Parkinson Disease. <i>JAMA Neurology</i> , 2020, 77, 1559.	9.0	66
35	F-box protein 7 mutations promote protein aggregation in mitochondria and inhibit mitophagy. <i>Human Molecular Genetics</i> , 2015, 24, 6314-6330.	2.9	64
36	Transducer-based evaluation of tremor. <i>Movement Disorders</i> , 2016, 31, 1327-1336.	3.9	64

#	ARTICLE	IF	CITATIONS
37	Gut microbiome modulates <i>Drosophila</i> aggression through octopamine signaling. <i>Nature Communications</i> , 2021, 12, 2698.	12.8	64
38	Alpha synuclein promoter and risk of Parkinson's disease: microsatellite and allelic size variability. <i>Neuroscience Letters</i> , 2003, 336, 70-72.	2.1	61
39	Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance. <i>Movement Disorders</i> , 2020, 35, 1755-1764.	3.9	57
40	Global investigation and meta-analysis of the C9orf72 (G ₄ C ₂) repeat in Parkinson disease. <i>Neurology</i> , 2014, 83, 1906-1913.	1.1	56
41	Essential tremor. <i>Nature Reviews Disease Primers</i> , 2021, 7, 83.	30.5	56
42	Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 997-1001.	3.9	55
43	Intermediate C9orf72 alleles in neurological disorders: does size really matter?. <i>Journal of Medical Genetics</i> , 2017, 54, 591-597.	3.2	52
44	Alpha-synuclein mRNA expression in sporadic Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 620-623.	3.9	48
45	Serum uric acid level and its association with motor subtypes and non-motor symptoms in early Parkinson's disease: PALS study. <i>Parkinsonism and Related Disorders</i> , 2018, 55, 50-54.	2.2	48
46	PD-linked CHCHD2 mutations impair CHCHD10 and MICOS complex leading to mitochondria dysfunction. <i>Human Molecular Genetics</i> , 2019, 28, 1100-1116.	2.9	48
47	Behind the facial twitch: depressive symptoms in hemifacial spasm. <i>Parkinsonism and Related Disorders</i> , 2005, 11, 241-245.	2.2	46
48	Association between caffeine intake and risk of Parkinson's disease among fast and slow metabolizers. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 1001-1005.	1.5	46
49	Transcallosal diffusion tensor abnormalities in predominant gait disorder parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 53-59.	2.2	46
50	Genetics of essential tremor. <i>Parkinsonism and Related Disorders</i> , 2016, 22, S176-S178.	2.2	46
51	Induced pluripotent stem cells in Parkinson's disease: scientific and clinical challenges. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 697-702.	1.9	45
52	Analysis of MDR1 haplotypes in Parkinson's disease in a white population. <i>Neuroscience Letters</i> , 2004, 372, 240-244.	2.1	44
53	Amyloid precursor protein regulates neurogenesis by antagonizing miR-574-5p in the developing cerebral cortex. <i>Nature Communications</i> , 2014, 5, 3330.	12.8	44
54	DI-3-n-Butylphthalide Rescues Dopaminergic Neurons in Parkinson's Disease Models by Inhibiting the NLRP3 Inflammasome and Ameliorating Mitochondrial Impairment. <i>Frontiers in Immunology</i> , 2021, 12, 794770.	4.8	44

#	ARTICLE	IF	CITATIONS
55	Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2020, 15, 33.	10.8	43
56	Lewy Body-like Inclusions in Human Midbrain Organoids Carrying Glucocerebrosidase and α -Synuclein Mutations. <i>Annals of Neurology</i> , 2021, 90, 490-505.	5.3	43
57	Thiol peroxidases ameliorate LRRK2 mutant-induced mitochondrial and dopaminergic neuronal degeneration in <i>Drosophila</i> . <i>Human Molecular Genetics</i> , 2014, 23, 3157-3165.	2.9	42
58	Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinson's disease. <i>Science Signaling</i> , 2017, 10, .	3.6	41
59	Differential White Matter Regional Alterations in Motor Subtypes of Early Drug-Naive Parkinson's Disease Patients. <i>Neurorehabilitation and Neural Repair</i> , 2018, 32, 129-141.	2.9	41
60	Comparing knowledge and attitudes towards genetic testing in Parkinson's disease in an American and Asian population. <i>Journal of the Neurological Sciences</i> , 2007, 252, 113-120.	0.6	40
61	Messaging Fatigue and Desensitisation to Information During Pandemic. <i>Archives of Medical Research</i> , 2020, 51, 716-717.	3.3	40
62	Oxidized nicotinamide adenine dinucleotide-dependent mitochondrial deacetylase sirtuin-3 as a potential therapeutic target of Parkinson's disease. <i>Ageing Research Reviews</i> , 2020, 62, 101107.	10.9	40
63	Deterministic Tractography of the Nigrostriatal-Nigropallidal Pathway in Parkinson's Disease. <i>Scientific Reports</i> , 2015, 5, 17283.	3.3	39
64	Targeting LRRK2 in Parkinson's disease: an update on recent developments. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 601-610.	3.4	39
65	Prospective longitudinal study of frailty transitions in a community-dwelling cohort of older adults with cognitive impairment. <i>BMC Geriatrics</i> , 2015, 15, 175.	2.7	38
66	Neural substrates of excessive daytime sleepiness in early drug naïve Parkinson's disease: A resting state functional MRI study. <i>Parkinsonism and Related Disorders</i> , 2016, 24, 63-68.	2.2	38
67	<i>SLC1A2</i> variant associated with essential tremor but not Parkinson disease in Chinese subjects. <i>Neurology</i> , 2013, 80, 1618-1619.	1.1	36
68	<i>NOTCH2NLC</i> GGC Repeat Expansions Are Associated with Sporadic Essential Tremor: Variable Disease Expressivity on Long-Term Follow-up. <i>Annals of Neurology</i> , 2020, 88, 614-618.	5.3	36
69	LRRK2 G2385R modulates age at onset in Parkinson's disease: A multicenter pooled analysis. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2009, 150B, 1022-1023.	1.7	35
70	In vivo evidence of pathogenicity of VPS35 mutations in the <i>Drosophila</i> . <i>Molecular Brain</i> , 2014, 7, 73.	2.6	35
71	White matter microstructural characteristics in newly diagnosed Parkinson's disease: An unbiased whole-brain study. <i>Scientific Reports</i> , 2016, 6, 35601.	3.3	35
72	Haplotype analysis at the <i>ETM2</i> locus in a Singaporean sample with familial essential tremor. <i>Clinical Genetics</i> , 2004, 66, 353-357.	2.0	33

#	ARTICLE	IF	CITATIONS
73	Analysis of <i>LRRK2</i> Gly2385Arg genetic variant in non-Chinese Asians. <i>Movement Disorders</i> , 2007, 22, 1816-1818.	3.9	33
74	Greater motor progression in patients with Parkinson disease who carry <i>LRRK2</i> risk variants. <i>Neurology</i> , 2015, 85, 1039-1042.	1.1	31
75	Structural connectome alterations in prodromal and de novo Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2017, 45, 21-27.	2.2	31
76	Pathophysiological mechanisms linking F-box only protein 7 (FBXO7) and Parkinson's disease (PD). <i>Mutation Research - Reviews in Mutation Research</i> , 2018, 778, 72-78.	5.5	30
77	Myorhythmia-slow facial tremor from chronic interferon alpha-2a usage. <i>Neurology</i> , 2003, 61, 1302-1303.	1.1	29
78	Severe bruxism following basal ganglia infarcts: insights into pathophysiology. <i>Journal of the Neurological Sciences</i> , 2004, 217, 229-232.	0.6	29
79	CHCHD2 and Parkinson's disease. <i>Lancet Neurology</i> , The, 2015, 14, 681-682.	10.2	29
80	Whole-exome sequencing in early-onset Parkinson's disease among ethnic Chinese. <i>Neurobiology of Aging</i> , 2020, 90, 150.e5-150.e11.	3.1	29
81	Vascular, inflammatory and metabolic risk factors in relation to dementia in Parkinson's disease patients with type 2 diabetes mellitus. <i>Aging</i> , 2020, 12, 15682-15704.	3.1	29
82	Monoamine oxidase B polymorphism, cigarette smoking and risk of Parkinson's disease: A study in an Asian population. <i>American Journal of Medical Genetics Part A</i> , 2003, 120B, 58-62.	2.4	28
83	Analysis of non-synonymous-coding variants of Parkinson's disease-related pathogenic and susceptibility genes in East Asian populations. <i>Human Molecular Genetics</i> , 2014, 23, 3891-3897.	2.9	28
84	Essential tremor linked TENM4 mutation found in healthy Chinese individuals. <i>Parkinsonism and Related Disorders</i> , 2016, 31, 139-140.	2.2	28
85	Dopamine D2 receptor TaqIA and TaqIB polymorphisms in Parkinson's disease. <i>Movement Disorders</i> , 2003, 18, 593-595.	3.9	27
86	An urge to move with L-thyroxine: Clinical, biochemical, and polysomnographic correlation. <i>Movement Disorders</i> , 2004, 19, 1365-1367.	3.9	27
87	Dietary cholesterol, fats and risk of Parkinson's disease in the Singapore Chinese Health Study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2014-310065.	1.9	27
88	Current Opinions and Consensus for Studying Tremor in Animal Models. <i>Cerebellum</i> , 2019, 18, 1036-1063.	2.5	27
89	Case-control study of UCHL1 S18Y variant in Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 1765-1768.	3.9	26
90	LRRK2 variant associated with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2011, 32, 1990-1993.	3.1	26

#	ARTICLE	IF	CITATIONS
91	Immature Midbrain Dopaminergic Neurons Derived from Floor-Plate Method Improve Cell Transplantation Therapy Efficacy for Parkinson's Disease. <i>Stem Cells Translational Medicine</i> , 2017, 6, 1803-1814.	3.3	26
92	Caseâ€“control study of anxiety symptoms in hemifacial spasm. <i>Movement Disorders</i> , 2006, 21, 2145-2149.	3.9	25
93	Delivering patient-centered care in Parkinson's disease: Challenges and consensus from an international panel. <i>Parkinsonism and Related Disorders</i> , 2020, 72, 82-87.	2.2	25
94	Genetic analysis of DJ-1 in a cohort Parkinsonâ€™s disease patients of different ethnicity. <i>Neuroscience Letters</i> , 2004, 367, 109-112.	2.1	24
95	Differential effect of caffeine intake in subjects with genetic susceptibility to Parkinsonâ€™s Disease. <i>Scientific Reports</i> , 2015, 5, 15492.	3.3	24
96	Mild cognitive impairment in Parkinsonâ€™s disease: a distinct clinical entity?. <i>Translational Neurodegeneration</i> , 2017, 6, 24.	8.0	24
97	Automated analysis of gait and modified timed up and go using the Microsoft Kinect in people with Parkinsonâ€™s disease: associations with physical outcome measures. <i>Medical and Biological Engineering and Computing</i> , 2019, 57, 369-377.	2.8	24
98	Capsaicin Functions as Drosophila Ovipositional Repellent and Causes Intestinal Dysplasia. <i>Scientific Reports</i> , 2020, 10, 9963.	3.3	24
99	Unravelling Pathophysiology of Neurological and Psychiatric Complications of COVID-19 Using Brain Organoids. <i>Neuroscientist</i> , 2023, 29, 30-40.	3.5	24
100	Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2005, 137B, 1-4.	1.7	23
101	Clinical characteristics of leg restlessness in Parkinson's disease compared with idiopathic Restless Legs Syndrome. <i>Journal of the Neurological Sciences</i> , 2015, 357, 109-114.	0.6	23
102	DNAJ mutations are rare in Chinese Parkinson's disease patients and controls. <i>Neurobiology of Aging</i> , 2014, 35, 935.e1-935.e2.	3.1	22
103	Varied pathological and therapeutic response effects associated with <i>CHCHD2</i> mutant and risk variants. <i>Human Mutation</i> , 2017, 38, 978-987.	2.5	21
104	Molecular targets for modulating the protein translation vital to proteostasis and neuron degeneration in Parkinsonâ€™s disease. <i>Translational Neurodegeneration</i> , 2019, 8, 6.	8.0	21
105	Various Diseases and Clinical Heterogeneity Are Associated With â€œHot Cross Bunâ€•. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 592212.	3.4	21
106	Dietary Antioxidants and Risk of Parkinson's Disease in the Singapore Chinese Health Study. <i>Movement Disorders</i> , 2020, 35, 1765-1773.	3.9	21
107	Subjective cognitive Complaints in early Parkinson's disease patients with normal cognition are associated with affective symptoms. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 24-28.	2.2	21
108	Restless Legs Syndrome and Parkinsonâ€™s Disease: Is there an etiologic link?. <i>Journal of Neurology</i> , 2006, 253, vii33-vii37.	3.6	20

#	ARTICLE	IF	CITATIONS
109	Genetic analysis of SCA 2 and 3 repeat expansions in essential tremor and atypical Parkinsonism. <i>Movement Disorders</i> , 2007, 22, 1971-1974.	3.9	20
110	In utero infection of Zika virus leads to abnormal central nervous system development in mice. <i>Scientific Reports</i> , 2019, 9, 7298.	3.3	20
111	Differentiating Parkinson's disease motor subtypes using automated volume-based morphometry incorporating white matter and deep gray nuclear lesion load. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 748-756.	3.4	20
112	Multimodal analysis of gene expression from postmortem brains and blood identifies synaptic vesicle trafficking genes to be associated with Parkinson's disease. <i>Briefings in Bioinformatics</i> , 2021, 22, .	6.5	20
113	"Hot cross bun" is a potential imaging marker for the severity of cerebellar ataxia in MSA-C. <i>Npj Parkinson's Disease</i> , 2021, 7, 15.	5.3	20
114	LRRK2 interacts with ATM and regulates Mdm2-p53 cell proliferation axis in response to genotoxic stress. <i>Human Molecular Genetics</i> , 2017, 26, 4494-4505.	2.9	19
115	Lrrk2 R1628P variant is a risk factor for essential tremor. <i>Scientific Reports</i> , 2015, 5, 9029.	3.3	18
116	GWAS-linked PPARGC1A variant in Asian patients with essential tremor. <i>Brain</i> , 2017, 140, e24-e24.	7.6	18
117	Microstructural network alterations of olfactory dysfunction in newly diagnosed Parkinson's disease. <i>Scientific Reports</i> , 2017, 7, 12559.	3.3	18
118	Modelling Alzheimer's disease: Insights from <i>in vivo</i> to <i>in vitro</i> three-dimensional culture platforms. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2018, 12, 1944-1958.	2.7	18
119	Identification of a common genetic risk variant (LRRK2 Gly2385Arg) in Parkinson's disease. <i>Annals of the Academy of Medicine, Singapore</i> , 2006, 35, 840-2.	0.4	18
120	Non-synonymous GIGYF2 variants in Parkinson's disease from two Asian populations. <i>Human Genetics</i> , 2009, 126, 425-430.	3.8	17
121	Higher serum triglyceride levels are associated with Parkinson's disease mild cognitive impairment. <i>Movement Disorders</i> , 2018, 33, 1970-1971.	3.9	17
122	Eosinophilic granulomatosis with polyangiitis after COVID-19 vaccination. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2022, 114, 807-809.	0.5	17
123	Neurodegenerative diseases associated with non-coding CGG tandem repeat expansions. <i>Nature Reviews Neurology</i> , 2022, 18, 145-157.	10.1	17
124	Mutant PINK1 upregulates tyrosine hydroxylase and dopamine levels, leading to vulnerability of dopaminergic neurons. <i>Free Radical Biology and Medicine</i> , 2014, 68, 220-233.	2.9	16
125	Analysis of GWAS-linked variants in multiple system atrophy. <i>Neurobiology of Aging</i> , 2018, 67, 201.e1-201.e4.	3.1	16
126	Fully automated leg tracking of Drosophila neurodegeneration models reveals distinct conserved movement signatures. <i>PLoS Biology</i> , 2019, 17, e3000346.	5.6	16

#	ARTICLE	IF	CITATIONS
127	New Insights into Immune-Mediated Mechanisms in Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9302.	4.1	16
128	Aggregation-induced emission (AIE) nanoparticles labeled human embryonic stem cells (hESCs)-derived neurons for transplantation. <i>Biomaterials</i> , 2021, 271, 120747.	11.4	16
129	Exploring an interaction of adenosine A2A receptor variability with coffee and tea intake in Parkinson's disease. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2006, 141B, 634-636.	1.7	15
130	Essential tremor and the common LRRK2 G2385R variant. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 569-571.	2.2	15
131	Revisiting the link between hypertension and hemifacial spasm. <i>Scientific Reports</i> , 2016, 6, 21082.	3.3	15
132	p62-Mediated mitochondrial clustering attenuates apoptosis induced by mitochondrial depolarization. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2017, 1864, 1308-1317.	4.1	15
133	The Characteristics of Patients Associated With High Caregiver Burden in Parkinson's Disease in Singapore. <i>Frontiers in Neurology</i> , 2019, 10, 561.	2.4	15
134	Plasma ubiquitin C-terminal hydrolase L1 levels reflect disease stage and motor severity in Parkinson's disease. <i>Aging</i> , 2020, 12, 1488-1495.	3.1	15
135	Treatment outcome correlates with knowledge of disease in hemifacial spasm. <i>Clinical Neurology and Neurosurgery</i> , 2008, 110, 813-817.	1.4	14
136	Case control analysis of LRRK2 Gly2385Arg in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2009, 30, 501-502.	3.1	14
137	Targeted exome sequencing reveals homozygous TREM2 R47C mutation presenting with behavioral variant frontotemporal dementia without bone involvement. <i>Neurobiology of Aging</i> , 2018, 68, 160.e15-160.e19.	3.1	14
138	Mental health of scientists in the time of COVID-19. <i>Brain, Behavior, and Immunity</i> , 2020, 88, 956.	4.1	14
139	Trans-ethnic Fine-Mapping of the Major Histocompatibility Complex Region Linked to Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 1805-1814.	3.9	14
140	Parkinson's disease and cancer: a systematic review and meta-analysis on the influence of lifestyle habits, genetic variants, and gender. <i>Aging</i> , 2022, 14, 2148-2173.	3.1	14
141	Linking LINGO1 to essential tremor. <i>European Journal of Human Genetics</i> , 2010, 18, 739-740.	2.8	13
142	Sexual dysfunction is associated with postural instability gait difficulty subtype of Parkinson's disease. <i>Journal of Neurology</i> , 2015, 262, 2433-2439.	3.6	13
143	SNCA Rep1 promoter variability influences cognition in Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1232-1236.	3.9	13
144	Paroxysmal movement disorders: Recent advances and proposal of a classification system. <i>Parkinsonism and Related Disorders</i> , 2019, 59, 131-139.	2.2	13

#	ARTICLE	IF	CITATIONS
145	Gutâ€œBrain Axis: Potential Factors Involved in the Pathogenesis of Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 849.	2.4	13
146	Vascular parkinsonism in moyamoya: Microvascular biopsy and imaging correlates. <i>Annals of Neurology</i> , 2003, 54, 836-840.	5.3	12
147	Pathogenicity of LRRK2 P755L variant in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 734-736.	3.9	12
148	Clinically reported heterozygous mutations in the PINK1 kinase domain exert a gene dosage effect. <i>Human Mutation</i> , 2009, 30, 1551-1557.	2.5	12
149	DTI Profiles for Rapid Description of Cohorts at the Clinical-Research Interface. <i>Frontiers in Medicine</i> , 2018, 5, 357.	2.6	12
150	Mitochondrial CHCHD2 and CHCHD10: Roles in Neurological Diseases and Therapeutic Implications. <i>Neuroscientist</i> , 2020, 26, 170-184.	3.5	12
151	Isolated facial myorhythmia. <i>Journal of the Neurological Sciences</i> , 2007, 252, 36-38.	0.6	11
152	A longitudinal study of non-motor symptom burden in Parkinson's disease after a transition to expert care. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 843-847.	2.2	11
153	<i>PARK16</i> is associated with PD in the Malaysian population. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2016, 171, 839-847.	1.7	11
154	Clinicopathological correlation of psychosis and brain vascular changes in Alzheimerâ€™s disease. <i>Scientific Reports</i> , 2016, 6, 20858.	3.3	11
155	Genes and Nonmotor Symptoms in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 133, 111-127.	2.0	11
156	B vitamins and cognition in subjects with small vessel disease: A Substudy of VITATOPS, a randomized, placebo-controlled trial. <i>Journal of the Neurological Sciences</i> , 2017, 379, 124-126.	0.6	11
157	Association of <i>LRRK2</i> Haplotype With Age at Onset in Parkinson Disease. <i>JAMA Neurology</i> , 2018, 75, 127.	9.0	11
158	<i>LRRK2</i> N551K and R1398H variants are protective in Malays and Chinese in Malaysia: A caseâ€œcontrol association study for Parkinson's disease. <i>Molecular Genetics & Genomic Medicine</i> , 2019, 7, e604.	1.2	11
159	LRRK2 G2019S founder haplotype in the Chinese population. <i>Movement Disorders</i> , 2007, 22, 105-107.	3.9	10
160	Genetic analysis of <i>CHCHD2</i> gene in Chinese Parkinson's disease. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2016, 171, 1148-1152.	1.7	10
161	Development of a human induced pluripotent stem cell (iPSC) line from a Parkinson's disease patient carrying the N551K variant in LRRK2 gene. <i>Stem Cell Research</i> , 2017, 18, 51-53.	0.7	10
162	Generation of a human induced pluripotent stem cell (iPSC) line carrying the Parkinsonâ€™s disease linked LRRK2 variant S1647T. <i>Stem Cell Research</i> , 2017, 18, 54-56.	0.7	10

#	ARTICLE	IF	CITATIONS
163	The impact of levodopa therapy-induced complications on quality of life in Parkinson's disease patients in Singapore. <i>Scientific Reports</i> , 2019, 9, 9248.	3.3	10
164	Altered striatal dopamine levels in Parkinson's disease VPS35 D620N mutant transgenic aged mice. <i>Molecular Brain</i> , 2020, 13, 164.	2.6	10
165	COVID-19 vaccination and cultural tightness. <i>Psychological Medicine</i> , 2023, 53, 1124-1125.	4.5	10
166	Autosomal Dominant Spinocerebellar Ataxias: An Asian Perspective. <i>Canadian Journal of Neurological Sciences</i> , 2003, 30, 361-367.	0.5	9
167	Interaction between SNCA, LRRK2 and GAK increases susceptibility to Parkinson's disease in a Chinese population. <i>ENeurologicalSci</i> , 2015, 1, 3-6.	1.3	9
168	Nonsynonymous variants in <i>MC1R</i> are rare in Chinese Parkinson disease cases. <i>Annals of Neurology</i> , 2015, 78, 152-153.	5.3	9
169	FUS-linked essential tremor associated with motor dysfunction in <i>Drosophila</i> . <i>Human Genetics</i> , 2016, 135, 1223-1232.	3.8	9
170	Patient-Centric Care for Parkinson's Disease: From Hospital to the Community. <i>Frontiers in Neurology</i> , 2020, 11, 502.	2.4	9
171	Mild Parkinsonian Signs in a Community Ambulant Population. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1231-1237.	2.8	9
172	Two heterozygous progranulin mutations in progressive supranuclear palsy. <i>Brain</i> , 2021, 144, e27-e27.	7.6	9
173	Utility of quantitative susceptibility mapping and diffusion kurtosis imaging in the diagnosis of early Parkinson's disease. <i>NeuroImage: Clinical</i> , 2021, 32, 102831.	2.7	9
174	Parkinson's disease following COVID-19: causal link or chance occurrence?. <i>Journal of Translational Medicine</i> , 2020, 18, 493.	4.4	9
175	Association Between Parkinson's Disease and Coronary Artery Disease: A Systematic Review and Meta-Analysis. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1737-1748.	2.8	9
176	Complex movement disorders following bilateral paramedian thalamic and bilateral cerebellar infarcts. <i>Movement Disorders</i> , 2001, 16, 968-970.	3.9	8
177	LRRK2 G2019S and I2020T mutations are not common in Alzheimer's disease and vascular dementia. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2006, 141B, 549-550.	1.7	8
178	Patterns of linkage disequilibrium at <i>PARK16</i> may explain variances in genetic association studies. <i>Movement Disorders</i> , 2015, 30, 1335-1342.	3.9	8
179	Large 3-Mb deletions at 22q11.2 locus in Parkinson's disease and schizophrenia. <i>Movement Disorders</i> , 2016, 31, 1924-1925.	3.9	8
180	Linking a genome-wide association study signal to a <i>LRRK2</i> coding variant in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 484-487.	3.9	8

#	ARTICLE	IF	CITATIONS
181	Screening for TMEM230 mutations in young-onset Parkinson's disease. <i>Neurobiology of Aging</i> , 2017, 58, 239.e9-239.e10.	3.1	8
182	Paroxysmal Movement Disorders: Recent Advances. <i>Current Neurology and Neuroscience Reports</i> , 2019, 19, 48.	4.2	8
183	Dopamine transporter neuroimaging accurately assesses the maturation of dopamine neurons in a preclinical model of Parkinson's disease. <i>Stem Cell Research and Therapy</i> , 2020, 11, 347.	5.5	8
184	Impaired neurogenesis in the hippocampus of an adult VPS35 mutant mouse model of Parkinson's disease through interaction with APP. <i>Neurobiology of Disease</i> , 2021, 153, 105313.	4.4	8
185	Case-control study of hypertension and Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 63.	5.3	8
186	Vascular tortuosity in relationship with hypertension and posterior fossa volume in hemifacial spasm. <i>BMC Neurology</i> , 2016, 16, 120.	1.8	7
187	Reprogramming of a human induced pluripotent stem cell (iPSC) line from a Parkinson's disease patient with a R1628P variant in the LRRK2 gene. <i>Stem Cell Research</i> , 2017, 18, 45-47.	0.7	7
188	Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study. <i>Neurobiology of Aging</i> , 2017, 49, 217.e1-217.e4.	3.1	7
189	G2019S LRRK2 Increases Stress Susceptibility Through Inhibition of DAF-16 Nuclear Translocation in a 14-3-3 Associated-Manner in <i>Caenorhabditis elegans</i> . <i>Frontiers in Neuroscience</i> , 2018, 12, 782.	2.8	7
190	Evaluation of novel Parkinson's disease candidate genes in the Chinese population. <i>Neurobiology of Aging</i> , 2019, 74, 235.e1-235.e4.	3.1	7
191	Olfactory dysfunction and COVID-19. <i>Lancet Psychiatry</i> , 2020, 7, 663.	7.4	7
192	Safeguarding Non-COVID-19 Research: Looking Up from Ground Zero. <i>Archives of Medical Research</i> , 2020, 51, 731-732.	3.3	7
193	Adapting to post-COVID19 research in Parkinson's disease: Lessons from a multinational experience. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 146-149.	2.2	7
194	Symbiotic bacteria attenuate <i>Drosophila</i> oviposition repellence to alkaline through acidification. <i>Insect Science</i> , 2021, 28, 403-414.	3.0	7
195	Increased expression of pathological markers in Parkinson's disease dementia post-mortem brains compared to dementia with Lewy bodies. <i>BMC Neuroscience</i> , 2022, 23, 3.	1.9	7
196	Psychogenic tics: diagnostic value of the placebo test. <i>Journal of Child Neurology</i> , 2004, 19, 976-7.	1.4	7
197	Restless hand symptoms in carpal tunnel syndrome. <i>International Journal of Clinical Practice</i> , 2004, 58, 1000-1002.	1.7	6
198	Evaluating LRRK2 Genetic Variants with Unclear Pathogenicity. <i>BioMed Research International</i> , 2015, 2015, 1-6.	1.9	6

#	ARTICLE	IF	CITATIONS
199	Familial Parkinson's Disease/Parkinsonism. BioMed Research International, 2015, 2015, 1-2.	1.9	6
200	Derivation of human induced pluripotent stem cell (iPSC) line with LRRK2 gene R1398H variant in Parkinson's disease. Stem Cell Research, 2017, 18, 48-50.	0.7	6
201	Parkinson's disease GWAS-linked Park16 carriers show greater motor progression. Journal of Medical Genetics, 2019, 56, 765-768.	3.2	6
202	Association analysis of <i>PSAP</i> variants in Parkinson's disease patients. Brain, 2021, 144, e9-e9.	7.6	6
203	Physical Activity Improves Anxiety and Apathy in Early Parkinson's Disease: A Longitudinal Follow-Up Study. Frontiers in Neurology, 2020, 11, 625897.	2.4	6
204	Remote Prescription During Pandemic: Challenges and Solutions. Archives of Medical Research, 2021, 52, 450-452.	3.3	6
205	The splenic angle: a novel radiological index for idiopathic normal pressure hydrocephalus. European Radiology, 2021, 31, 9086-9097.	4.5	6
206	Functional Neurological Disorders and COVID-19 Vaccination. Annals of Neurology, 2021, 90, 328-328.	5.3	6
207	Clinical correlates of white matter lesions in Parkinson's disease using automated multi-modal segmentation measures. Journal of the Neurological Sciences, 2021, 427, 117518.	0.6	6
208	Blood Lipid Biomarkers in Early Parkinson's Disease and Parkinson's Disease with Mild Cognitive Impairment. Journal of Parkinson's Disease, 2022, 12, 1937-1943.	2.8	6
209	Trigeminal neuralgia: should MRI be done routinely?. Australian and New Zealand Journal of Medicine, 1998, 28, 827-829.	0.5	5
210	Dopamine agonists and their role in Parkinson's disease treatment. Expert Review of Neurotherapeutics, 2003, 3, 805-810.	2.8	5
211	Bilateral trapezius hypertrophy with dystonia and atrophy. Cmaj, 2007, 176, 1702-1703.	2.0	5
212	Neurovascular compression syndromes and hypertension: clinical relevance. Nature Clinical Practice Neurology, 2007, 3, 416-417.	2.5	5
213	Test-retest repeatability of assessing environmental and lifestyle factors in Parkinson's disease. Movement Disorders, 2008, 23, 1032-1036.	3.9	5
214	Rare and common LRRK2 exonic variants in Parkinson's disease. Lancet Neurology, The, 2011, 10, 869-870.	10.2	5
215	Case-control analysis of LRRK2 protective variants in Essential Tremor. Scientific Reports, 2018, 8, 5346.	3.3	5
216	Increased Activation of Default Mode Network in Early Parkinson's With Excessive Daytime Sleepiness. Frontiers in Neuroscience, 2019, 13, 1334.	2.8	5

#	ARTICLE	IF	CITATIONS
217	Association study of MCCC1/LAMP3 and DGKQ variants with Parkinson's disease in patients of Malay ancestry. <i>Neurological Sciences</i> , 2021, 42, 4203-4207.	1.9	5
218	Applying Artificial Intelligence to Multi-Omic Data: New Functional Variants in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 347-347.	3.9	5
219	Stroke-related restless legs syndrome: epidemiology, clinical characteristics and pathophysiology. <i>Sleep Medicine</i> , 2022, 90, 238-248.	1.6	5
220	Chromosomal deletion at 22q11.2 and Parkinson's disease. <i>Lancet Neurology</i> , The, 2016, 15, 538-540.	10.2	4
221	Linking statins and lipids in Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 807-809.	3.9	4
222	ITPKB and ZNF184 are associated with Parkinson's disease risk in East Asians. <i>Neurobiology of Aging</i> , 2020, 86, 201.e15-201.e17.	3.1	4
223	Four-Year Longitudinal Study of Motor and Non-motor Symptoms in LRRK2-Related Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 1379.	2.4	4
224	Stability of MDS-UPDRS Motor Subtypes Over Three Years in Early Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 704906.	2.4	4
225	COVID-19 vaccination precipitating <i>de novo</i> ANCA-associated vasculitis: clinical implications. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1010-1011.	2.9	4
226	Parkinson's Disease-Specific Autoantibodies against the Neuroprotective Co-Chaperone STIP1. <i>Cells</i> , 2022, 11, 1649.	4.1	4
227	No Association of Four Candidate Genetic Variants in MnSOD and SYNIII with Parkinson's Disease in Two Chinese Populations. <i>PLoS ONE</i> , 2014, 9, e88050.	2.5	3
228	Sleep Problems in Parkinson's Disease. <i>Parkinson's Disease</i> , 2015, 2015, 1-2.	1.1	3
229	Characteristics of Chinese-English bilingual dyslexia in right occipito-temporal lesion. <i>Journal of Clinical Neuroscience</i> , 2017, 45, 146-148.	1.5	3
230	Case-control analysis of leucine-rich repeat kinase 2 protective variants in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 64, 157.e7-157.e9.	3.1	3
231	Neurological research & training after the easing of lockdown in countries impacted by COVID-19. <i>Journal of the Neurological Sciences</i> , 2020, 418, 117105.	0.6	3
232	Movement disorders in 2020: clinical trials, genetic discoveries, and COVID-19. <i>Lancet Neurology</i> , The, 2021, 20, 10-12.	10.2	3
233	High Diagnostic Utility Incorporating a Targeted Neurodegeneration Gene Panel With MRI Brain Diagnostic Algorithms in Patients With Young-Onset Cognitive Impairment With Leukodystrophy. <i>Frontiers in Neurology</i> , 2021, 12, 631407.	2.4	3
234	Polygenic Risk Scores in a Prospective Parkinson's Disease Cohort. <i>Movement Disorders</i> , 2021, 36, 2936.	3.9	3

#	ARTICLE	IF	CITATIONS
235	Leucine-Rich Repeat Kinase 2-Linked Parkinson's Disease: Clinical and Molecular Findings. <i>Journal of Movement Disorders</i> , 2010, 3, 25-31.	1.3	3
236	Multiple System Atrophy (MSA) and smoking: a meta-analysis and mechanistic insights. <i>Aging</i> , 2020, 12, 21959-21970.	3.1	3
237	Prognosis of Guillain-Barré Syndrome Linked to COVID-19 Vaccination. <i>Brain Sciences</i> , 2022, 12, 711.	2.3	3
238	Neurodegeneration: Etiologies and New Therapies 2016. <i>BioMed Research International</i> , 2016, 2016, 1-1.	1.9	2
239	Risk factors for respiratory failure of motor neuron disease in a multiracial Asian population. <i>Journal of Clinical Neuroscience</i> , 2017, 39, 137-141.	1.5	2
240	Positive predictive value of different methods for identifying Parkinson's disease cases in an epidemiological study. <i>Parkinsonism and Related Disorders</i> , 2018, 54, 119-120.	2.2	2
241	Association between plasma neurofilament light chain levels and cognition in early Parkinson's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e040206.	0.8	2
242	Appropriateness of MRI brain orders: Application of American and British guidelines. <i>Journal of the Neurological Sciences</i> , 2020, 414, 116874.	0.6	2
243	Evidence of Added Value of Chest CT in Coronavirus Disease (COVID-19) Pneumonia With Initial Negative RT-PCR Results. <i>American Journal of Roentgenology</i> , 2020, 215, W41-W41.	2.2	2
244	Prognostic factors of key outcomes for motor neuron disease in a multiracial Asian population. <i>Journal of Clinical Neuroscience</i> , 2020, 72, 63-67.	1.5	2
245	Neurovascular compression in hemifacial spasm. <i>Brain</i> , 2021, . .	7.6	2
246	<i>SNCA</i> Rep1 microsatellite length influences non-motor symptoms in early Parkinson's disease. <i>Aging</i> , 2020, 12, 20880-20887.	3.1	2
247	Upregulated Blood miR-150-5p in Alzheimer's Disease Dementia Is Associated with Cognition, Cerebrospinal Fluid Amyloid- β , and Cerebral Atrophy. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1567-1584.	2.6	2
248	Utility of next-generation sequencing in ataxias. <i>Nature Reviews Neurology</i> , 2013, 9, 614-615.	10.1	1
249	Plasma Vitamin D Levels are Lower among Ethnic Indians in Matched Pairs of Male Acute Ischaemic Stroke Patients of Indian and Chinese Ethnicity. <i>Proceedings of Singapore Healthcare</i> , 2013, 22, 163-165.	0.6	1
250	Association Analysis of COQ2 Variant in Dementia and Essential Tremor. <i>Parkinson's Disease</i> , 2015, 2015, 1-4.	1.1	1
251	Towards better cellular replacement therapies in Parkinson disease. <i>Journal of Neuroscience Research</i> , 2018, 96, 219-221.	2.9	1
252	Chest CT in asymptomatic COVID-19: benefits and concerns. <i>Quantitative Imaging in Medicine and Surgery</i> , 2020, 10, 1570-1571.	2.0	1

#	ARTICLE	IF	CITATIONS
253	Complete Genome Sequence of <i>Serratia marcescens</i> FY, Isolated from <i>Drosophila melanogaster</i> . <i>Microbiology Resource Announcements</i> , 2020, 9, .	0.6	1
254	Caution in Interpreting Facial Paralysis Data to Understand COVID-19 Vaccination Risks. <i>JAMA Internal Medicine</i> , 2021, 181, 1420.	5.1	1
255	Genetic marker linking inflammation with sporadic Parkinson's disease. <i>Annals of the Academy of Medicine, Singapore</i> , 2011, 40, 111-2.	0.4	1
256	Survival outcome of haemodialysis and peritoneal dialysis. <i>Annals of the Academy of Medicine, Singapore</i> , 2022, 51, 132-133.	0.4	1
257	Editorial: The Role of Neurovascular Unit in Neurodegeneration. <i>Frontiers in Cellular Neuroscience</i> , 2022, 16, 870631.	3.7	1
258	Mutant VPS35-D620N induces motor dysfunction and impairs DAT-mediated dopamine recycling pathway. <i>Human Molecular Genetics</i> , 2022, 31, 3886-3896.	2.9	1
259	Genetics of restless legs syndrome: evidence for a hereditary disorder. <i>Journal of Neurology</i> , 2007, 254, 68-73.	3.6	0
260	The borderland between epilepsy and movement disorders. , 0, , 333-351.		0
261	Considerations of Long-term Pain Evaluation Post“Deep Brain Stimulation Surgery. <i>JAMA Neurology</i> , 2015, 72, 1077.	9.0	0
262	Plasma Coenzyme Q10 Levels and Multiple System Atrophy. <i>JAMA Neurology</i> , 2016, 73, 1499.	9.0	0
263	Identifying genes in Parkinson disease: state of the art. <i>Medical Journal of Australia</i> , 2018, 208, 381-382.	1.7	0
264	20“...Clinical characteristics of pathological confirmed early onset dementia with lewy bodies. , 2019, , .		0
265	Questions on NOTCH2NLC Repeat Expansions in Parkinson Disease“Reply. <i>JAMA Neurology</i> , 2021, 78, 763.	9.0	0
266	Seasonal haze: Knowledge gaps and risk perception behaviours. <i>Annals of the Academy of Medicine, Singapore</i> , 2021, 50, 512-513.	0.4	0
267	Genetic Studies of Parkinson's and Alzheimer's Disease in Latinos/Hispanics: New Insights and Challenges. <i>Annals of Neurology</i> , 2021, 90, 350-352.	5.3	0
268	Fist-Edge-Palm (FEP) test has a high sensitivity in differentiating dementia from normal cognition in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2021, 429, 118060.	0.6	0
269	Longitudinal Study of SNCA Rep1 Polymorphism on Executive Function in“Early Parkinson“™s Disease. <i>Journal of Parkinson's Disease</i> , 2022, , 1-6.	2.8	0
270	Abstract WMP53: Vitamin D Levels Are Lower In Acute Ischemic Stroke Patients Compared To Matched Controls. <i>Stroke</i> , 2013, 44, .	2.0	0

#	ARTICLE	IF	CITATIONS
271	Abstract T P147: Vitamin D Deficiency is Associated With Stroke in ethnic Chinese but Not South Asians in a Case-Control Study. Stroke, 2014, 45, .	2.0	0